PDS Biotechnology (NASDAQ:PDSB) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS

PDS Biotechnology (NASDAQ:PDSB) released its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.10, Zacks reports.

PDS Biotechnology Stock Performance

Shares of PDSB opened at $1.24 on Thursday. The stock has a 50-day moving average of $1.41 and a 200-day moving average of $2.18. PDS Biotechnology has a one year low of $1.13 and a one year high of $4.56. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The company has a market cap of $47.36 million, a PE ratio of -1.06 and a beta of 1.68.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research note on Thursday, March 13th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.